CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 180 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03710824
NCT03710824N/ACompleted
CompareCT.gov

Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib

Boehringer Ingelheim·observational·Posted Oct 18, 2018·Updated Jul 31, 2024

In Brief

An observational study evaluating Nintedanib for Idiopathic Pulmonary Fibrosis. Completed, enrolled 180 participants across 10 sites.

Detailed Summary

Multi-center, non-interventional, prospective cohort study aiming to enroll 240 Idiopathic Pulmonary Fibrosis patients receiving treatment with nintedanib in a consecutive manner from 10-12 reference centers across Greece.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 18, 2018
Enrollment StartFeb 28, 2019
Primary CompletionFeb 22, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.7 years ago

Interventions

Nintedanibdrug

diagnosed IPF patients initiating treatment with nintedanib